Abstract: A system architecture for grid electrical energy storage comprising substantial numbers of cells connected in parallel. The lowest level of modularity comprising about eighteen or more individual cells connected in parallel. The disclosed architecture reduces the number of parts, complexity, and variability, while increasing one or more of reliability, service life, and energy capacity of a large-scale grid energy storage system, relative to a conventional multi-parallel string architecture.

Abstract: Provided are devices and methods for reducing or preventing fluid flow through a catheter lumen. For example, the devices and methods can be used to reduce blood flow through a catheter. Optionally, the catheter is an intravenous catheter.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder.

Abstract: The present invention belongs to the field of sustained drug release, and provides drug delivery compositions and methods of manufacturing drug delivery compositions.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.

Abstract: A drug-delivery composition includes an intermediate composition having a hydrophilic matrix of a cross-linked polymer in form of particles, and a pharmaceutically active composition distributed in the cross-linked polymer of the particles.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.

Abstract: Embodiments described herein relate to hydrophilic matrix material and sustained drug-delivery material, and their use in medical and cosmetic applications.

Abstract: A practice ball can comprise a coating on a plastic substantially spherical core having a solid continuous outer surface and a hollow interior. Raised laces features can extend from the outer surface of the core. The coating can also disposed on the raised laces features, and a portion of the coating on the raised laces features can extend from an outer surface of the coating on the outer surface of the core.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder.

Abstract: Provided are devices and methods for reducing or preventing fluid flow through a catheter lumen. For example, the devices and methods can be used to reduce blood flow through a catheter. Optionally, the catheter is an intravenous catheter. Also provided are catheters.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least one pharmaceutically active compound, a dry powder comprising at least a polymer, and an aqueous solution. The dry powder, the pharmaceutically active compound and the aqueous solution are mixed to form a paste-like or semi-solid drug-delivery composition, wherein the aqueous solution is added in an amount of less than or equal to twice the total dry mass of the dry powder.

Abstract: This invention relates to the use of novel glass materials comprising rare earth aluminate glasses (REA1™ glasses) in the gain medium of solid state laser devices that produce light at infrared wavelengths, typically in the range 1000 to 3000 nm and for infrared optics with transmission to approximately 5000 nm in thin sections. The novel glass materials provide stable hosts for trivalent ytterbium (Yb3+) ions and other optically active species or combinations of optically active species that exhibit fluorescence and that can be optically excited by the application of light. The glass gain medium can be configured as a waveguide or placed in an external laser cavity, or otherwise arranged to achieve gain in the laser waveband and so produce laser action.

Abstract: A topical eye solution for the treatment of corneal, scleral, or conjunctival diseases. In one embodiment of the present invention, the eye solution comprises a saline-based fluid, and an effective amount of at least one therapeutic compound or agent, wherein when at least one drop of the eye solution is applied to the surface of an eye, the therapeutic compound or agent is released to the cornea and conjunctiva of the eye.

Abstract: This invention relates to the use of novel glass materials comprising rare earth aluminate glasses (REA1™ glasses) in the gain medium of solid state laser devices that produce light at infrared wavelengths, typically in the range 1000 to 3000 nm and for infrared optics with transmission to approximately 5000 nm in thin sections. The novel glass materials provide stable hosts for trivalent ytterbium (Yb3+) ions and other optically active species or combinations of optically active species that exhibit fluorescence and that can be optically excited by the application of light. The glass gain medium can be configured as a waveguide or placed in an external laser cavity, or otherwise arranged to achieve gain in the laser waveband and so produce laser action.

Abstract: An implant for intraocular drug delivery for the treatment of inflammatory or degenerative diseases. In one embodiment, the implant includes a body portion having a first end portion and a second, opposite end portion and defining a cavity with a first opening at the first end portion, and a second, opposite opening at the second end portion, and a solid material received in the cavity, wherein the solid material comprises a depot material and an effective amount of at least one therapeutic compound or agent. When the implant is implanted in an eye of a living subject, the effective amount of at least one therapeutic compound or agent is released to the environment of the implant through at least one of the first opening and the second, opposite opening over an extended period of time.

Abstract: A separator is disclosed for moving a separated portion of an eye. The separator includes an upper surface. A lower planar surface is oriented at an angle with respect to the upper surface. The upper surface and the lower planar surface define an edge therebetween having a structure to remove a portion of an eye. The upper surface includes a structure to receive the removed portion of the eye and to roll the removed portion.